HIV-1 drug resistance among naïve patients in Armenia in 2017–2021
Journal of microbiology, epidemiology and immunobiology · 10.05.2024 · 101 (2) · 184-192
DOI: 10.36233/0372-9311-398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of microbiology, epidemiology and immunobiology, online erschienen am 10.05.2024. Verfasst von Olga A. Osadchaya und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The increased antiretroviral therapy (ART) coverage of patients in the absence of routine drug resistance (DR) tests highlight the importance of HIV-1 drug resistance surveillance in Armenia.
Aim
The aim of this study was a determination of the prevalence of HIV-1 DR on a large-scale cohort of HIV-infected citizens of the Republic of Armenia who had no experience of taking antiretroviral drugs. Materials and methods. The study was carried out on a cohort of more than 20% of PLHIV in the Republic of Armenia. The resulting 982 nucleotide sequences of the HIV-1 pol gene fragment, encoding the protease and reverse transcriptase region, as well as 367 sequences of the integrase gene, were analyzed using the Stanford University database and the CPR tool for the presence of drug resistance mutations and determination of the resistance level to ARV drugs. The HIV-1 subtype was determined using the Stanford University database and confirmed by phylogenetic analysis.
Results
The overall prevalence of HIV DR to ARV drugs in naïve patients was 13.8%. Resistance to non-nucleoside reverse transcriptase inhibitors was 11.2%, nucleotide reverse transcriptase inhibitors — 1.4%, protease inhibitors — 2.0% and integrase inhibitors — 0.5%. The predominant genetic variant among viruses containing DR mutations was subtype B. Resistance was most often recorded among men who have sex with men living in Yerevan.
Conclusion
In our study, prevalence of DR was high only for the NNRTI drugs. The results show that the first-line ARV drugs recommended in current national guidelines are highly likely to be effective. The analysis was carried out on a significant proportion of HIV-infected citizens of the Republic of Armenia, which increases the reliability and accuracy of the data obtained.
Zitieren
APA
Osadchaya, O. A., Kireev, D. E., Saleeva, D. V., Kirichenko, A. A., Lapovok, I. A., Lopatukhin, A. E., Shlykova, A. V., Makhmudova, L. F., Ladnaya, N. N., Hovakimyan, E. M., Martoyan, S. V., Kazaryan, H. K., Hovsepyan, T. V., Sargsiants, N. K., & Pokrovsky, V. V. (2024). HIV-1 drug resistance among naïve patients in Armenia in 2017–2021. Journal of microbiology, epidemiology and immunobiology, 101(2), 184-192. https://doi.org/10.36233/0372-9311-398
Vancouver
Osadchaya OA, Kireev DE, Saleeva DV, Kirichenko AA, Lapovok IA, Lopatukhin AE, et al. HIV-1 drug resistance among naïve patients in Armenia in 2017–2021. Journal of microbiology, epidemiology and immunobiology. 2024;101(2):184-192. doi:10.36233/0372-9311-398
BibTeX
@article{Osadchaya2024,
author = {Osadchaya, Olga A. and Kireev, Dmitry E. and Saleeva, Daria V. and Kirichenko, Alina A. and Lapovok, Ilya A. and Lopatukhin, Alexey E. and Shlykova, Anastasia V. and Makhmudova, Leila F. and Ladnaya, Natalia N. and Hovakimyan, Ermis M. and Martoyan, Siranush V. and Kazaryan, Hovsep K. and Hovsepyan, Tamara V. and Sargsiants, Narina K. and Pokrovsky, Vadim V.},
title = {HIV-1 drug resistance among naïve patients in Armenia in 2017–2021},
journal = {Journal of microbiology, epidemiology and immunobiology},
year = {2024},
volume = {101},
number = {2},
pages = {184--192},
doi = {10.36233/0372-9311-398}
}
EUVIMED